NCT06815471

CRF2 Agonist for the Treatment of Worsening Heart Failure

Corticotrophin Releasing Factor 2 for the Treatment of Worsening Heart Failure (WHF) - The CRAFT-WHF Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Corteria Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Detailed description

This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the dose-dependent effects of 3 doses of the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167, in subjects with WHF, defined as subjects requiring urgent administration of intravenous (i.v.) diuretics due to worsening of signs and symptoms of heart failure (HF) associated with volume overload

Conditions

• Worsening Heart Failure

Interventions

Type	Name	Description
DRUG	COR-1167	28-day treatment
DRUG	Placebo	28-day treatment

Timeline

• Start date: 2025-08-07
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-02-07
• Last updated: 2026-04-08

Locations

55 sites across 8 countries: United States, Czechia, Georgia, Hungary, Poland, Romania, Serbia, Spain

Regulatory

• FDA-regulated drug study